The New Jersey pharmaceutical company supplying ivermectin to a UK trial that was paused for a short period of time, says there are no supply issues with its pills.
Ivermectin is being investigated as part of the government-backed Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses (PRINCIPLE) in the United Kingdom as a possible home treatment for COVID-19, the disease caused by the CCP (Chinese Communist Party) virus. The trial was put on hold due to “temporary supply issues” as reported by Medpage Today on Dec. 14.
Details were not provided on the cause of the supply issues. The trial’s joint chief investigator, professor Chris Butler, and the trial’s press team declined to comment and respond to a query asking when the supply issue is expected to be resolved.
The Epoch Times also reached out to Torbay and South Devon NHS Foundation Trust in England—one of two organizations responsible for QP (quality person) release, importing, and, labeling of ivermectin in the trial—but did not receive a reply.
Daniel Worley Jr., Vice President of Business Development and Associate General Counsel of Edinbridge Pharmaceuticals, the manufacturer supplying the medicine, told The Epoch Times in an email that the company “is not experiencing any supply issues related to its ivermectin tablets (3mg) product.”
The company’s ivermectin tablets were added to the World Health Organization’s (WHO) Prequalified Medicines List last year in September, which ensures that a medicine meets “acceptable standards of quality, safety, and efficacy” for international procurement agencies to purchase and distribute in “resource-limited countries.” The list is part of the United Nation’s Prequalification of Medicines Programme and is run by the WHO.
The halt on the trial has since been lifted as of Friday. However, PRINCIPLE says it is now pausing “for registrations over the Festive Break” and will “reopen for registrations on January 4th,” according to the trial’s website.
Doctors Question Lack of Ivermectin Supply
When PRINCIPLE announced its ivermectin trial in June 2021, Butler, the co-chief investigator, said the drug was safe and readily available, suggesting that there was an appropriate supply of the drug.
“Ivermectin is readily available globally, has been in wide use for many other infectious conditions, so it’s a well-known medicine with a good safety profile, and because of the early promising results in some studies it is already being widely used to treat COVID-19 in several countries,” Butler said in a news release.
Several doctors questioned the sudden pause on the PRINCIPLE trial as a result of the ivermectin supply.
Dr. Tess Lawrie, director of the Evidence-based Medicine Consultancy, said the supply issue cited was “plainly ridiculous.” The WHO is one of Lawrie’s company’s clientele.
“To cite supply issues is plainly ridiculous,” Lawrie told The Epoch Times via email. “We are talking about a most abundant off-patent medicine that is produced in many countries around the world. There are many European manufacturers too, including Huvepharma in Bulgaria.”
Chief of the Division of Pulmonary and Critical Care Medicine at the Eastern Virginia Medical School Dr. Paul Marik said the reason given by PRINCIPLE was “nonsense.”
“It’s clear this is an ominous plot. A supply issue with IVERMECTIN; you must be kidding,” Marik told The Epoch Times in an email. “After 3.7 BILLION doses have been dispensed in the last 2 decades; we have a supply issue; what nonsense.”
Marik is also the co-founder of a medical organization called the Front Line COVID-19 Critical Care (FLCCC) Alliance that has developed several COVID-19 treatment protocols using ivermectin as “a core medication in the prevention and treatment” along with other medicines that are federally approved, “inexpensive, readily available, and have been used for decades with well-established safety profiles.”
Dr. Robert Malone, the inventor of the messenger RNA vaccine technology, says that it is unlikely there is a shortage of ivermectin, alleging the Oxford University team was either lying or incompetent.
“The first thing you do before you launch the study is you lock down your trial supply so that one completely fails the sniff test,” Malone said on Fox’s “The Ingraham Angle” show.
“Either they’re grossly incompetent at the University of Oxford or lying. It’s one or the other because [the] worldwide supply of ivermectin is enormous, and there’s no way that a competent clinical research team would not have locked down their trial supply.”
The Oxford University trial team did not reply to The Epoch Times’ request for comment.
The U.S. Food and Drug Administration (FDA), the WHO, and the European Medicines Agency advises against the use of the anti-parasitic drug for COVID-19, claiming that more data are needed on its effectiveness and safety. Still, some countries like Mexico and Uttar Pradesh, India, widely made ivermectin available as part of their treatment protocol to treat COVID-19.
Proponents of the drug say that the oral FDA-approved ivermectin formulation for humans, which comes in tablet forms, has a high safety profile. About 4.4 billion doses of the medicine (renamed Mectizan) have been administered in 49 countries to treat river blindness and lymphatic filariasis since 1987. In 2020 alone, “a total of 417 million Mectizan treatments were approved,” according to the Mectizan Donation Program (pdf).
According to the National Institutes of Health (NIH), ivermectin is “generally well tolerated” with minimal side effects that include dizziness, nausea, or diarrhea. The NIH neither recommends for nor against the use of ivermectin for COVID-19.
In addition, world-known French toxicologist, Prof. Jacques Descotes, in his comprehensive assessment of the safety profile of ivermectin based on an analysis of more than 350 articles, concluded that “the safety profile of ivermectin has so far been excellent in the majority of treated human patients so that ivermectin human toxicity cannot be claimed to be a serious cause for concern.”
He also wrote in his analysis (pdf) that, “The present extensive review of adverse events reportedly associated with ivermectin treatment for [the] therapeutic or prophylactic purpose did not reveal any significant cause for concern. … In fact, adverse events were mainly mild to moderate and infrequent.”
Get Ivermectin to your doorstep from the below Store
http://www.allmedsdoor.com
Buy Ivermectin
My only comment is that I wish that whoever writes the headlines knew how to spell. I see it often here; of course the writers are from different parts of the world, which might explain it. .
There’s a huge difference in meaning, between “principle ” and “principal”…
@Adam
Yes, that is an important question. IVM is available for prescription by a doctor willing to prescribe it and a pharmacy willing to dispense it. There are various sources for this and here are a few:
https://frontlinemds.com/intakeform/
https://myfreedoctor.com/
https://aflds.org/
https://sevencells.com/
https://myedpill.com/
https://www.alldaychemist.com/
https://flccc.net/
doctor: https://covid19criticalcare.com/ivermectin-in-covid-19/covid-19-care-providers/
Pharmacy: https://covid19criticalcare.com/pharmacies/
The last two lines are a list of doctors and pharmacies, respectively, that work with FLCCC. The list is always changing with regards to who might and might not still be prescribing and dispensing IVM, so call before going.
There is a new move by the USPS to interdict shipments of IVM, this is terrible but true. Hence if buying in bulk from a pharmacist via mail, be aware of this risk.
Dr. Zelenko and Dr. Immanuel have each created a pill including quercetin+Zn+other vitamins
as a prophylaxis tablet. Mind you it does not have IVM but the quercetin cocktails can still be useful in preventing disease.
Here are their sites for their respective products:
https://vladimirzelenkomd.com/
(called Z-stack)
https://pay.frontlinemds.com/marketplace/payment
(called Covivits)
@ peloni,One very important question that this article does not address, and I think should have addressed, is whether ivermectin is available in the United States as a prophylaxis and or treatment for COVID19. Peloni, do you have any recommendations for how to obtain ivermectin for either or both of these purposes in the United States?
Of course this was obvious for anyone who would think about it. Who would be squandering the supply of IVM as it is blocked from popular use around the globe in all but a few locations. India, the largest source of demand, has its own IVM production facilities.
The Oxford trial, unfortunately for England, did not include the entire English population. The trial doesn’t even have 10K participants and many of these, probably half, will not be recieving IVM. These claims are just silly and it is just more support for the govt-medical coordination creating and supporting the false notion that safe and effective treatment is not available for this disease, as more than 6K people continue to die every day world wide. Such willful ignorance is transparently obvious for any rational mind to consider. They just have to be willing to do so.